The first ever early clinical trial for a vaccine for genital chlamydia has shown it to be safe and effective at provoking an immune response.
The latest findings, from a randomised controlled trial of 35 healthy women led by Imperial College London and the Statens Serum Institut in Copenhagen, demonstrate promising early signs of what could be an effective vaccine against chlamydia.
The infection is the most common bacterial sexually transmitted infection (STI) worldwide and it can lead to infertility.
One of the problems we see is that people get repeatedly re-infected. If you could introduce a protective vaccine, you could break that cycle. Professor Robin Shattock Department of Infectious Disease
The researchers highlight that the work is an ‘important first step’ but add that further trials are now needed to determine whether the immune response provoked by the vaccine will effectively protect against chlamydia infection.
Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at Imperial said: “The findings are encouraging as they show the vaccine is safe and produces the type of immune response that could potentially protect against chlamydia.
“The next step is to take the vaccine forward to further trials, but until that’s done, we won’t know whether it is truly protective or not.”
Most prevalent bacterial STI
Chlamydia trachomatis is one of the most prevalent bacterial STIs, representing a major global health burden, with 131 million new cases occurring each year. However, as many as 3 out of 4 infections are symptomless, so the number of cases is likely to be underestimated.
National screening programmes and antibiotic treatment have failed to reduce infection rates, and the highest number of new cases are found in teenagers and young adults.
While infection can often be treated with antibiotics, complications can include inflammation, infertility, ectopic pregnancy, arthritis and even an increased susceptibility to other STIs, including HIV.
“The major issue with chlamydia is the long-term consequences,” explained Professor Shattock. “It is very treatable if identified, but as many people don’t have symptoms it can be missed, and the biggest problem is that it can go on to cause infertility in women.”
He added: “One of the problems we see with current efforts to treat chlamydia is that despite a very big screening, test and treat programme, people get repeatedly re-infected. If you could introduce a protective vaccine, you could break that cycle.”
Encouraging early results
In the latest trial, researchers compared two different formulations of the new vaccine to examine which would perform better. The 35 women not infected with chlamydia included in the trial were randomly assigned to three different groups: 15 participants received the vaccine with liposomes, 15 received the vaccine with aluminium hydroxide, and 5 received saline solution (placebo).
In total, participants received five vaccinations with three intramuscular injections in the arm over several months, followed by two intranasal boosts.
Both formulations of the vaccine provoked an immune response in 100% of participants, whereas no participants in the placebo group achieved an immune response.
Although both formulations of the vaccine were found to provoke an immune response, the added liposomes consistently performed better and produced more antibodies, so the authors suggest this formulation should be pursued for further clinical development.
The full findings are published in the journal The Lancet Infectious Diseases. The group is now planning phase 2 trials.
UK risks being ‘left behind’
The research was made possible through grants from the European Commission. Professor Shattock raised concerns about the future of such international collaborations and whether UK institutions can maintain their leading role in vaccine research.
“Increasingly vaccine development requires multiple partners,” said Professor Shattock. “We have a wealth of world-leading expertise in the UK, with our scientists working to tackle infections, and to discover and develop new vaccines. But if we are no longer part of that European network we may be left behind.
“It’s not just about the funding, it’s about being part of these larger projects that bring together companies and academics and a much wider portfolio of experience, technology and expertise to solve global health problems.”
The Latest on: Chlamydia
via Google News
The Latest on: Chlamydia
- STD’s Are Now Being Called Sexist Against Womenon October 28, 2019 at 2:33 pm
“Chlamydia and gonorrhea, for example, are two of the leading preventable causes of infertility and ectopic pregnancies in the United States, and on Earth.” It also appears that they are biologically ...
- Lindsey v. State Of Texason October 27, 2019 at 9:09 pm
Although the complainant’s younger brother did not testify, the trial court permitted the State to present evidence of an extraneous offense against the younger brother based in part on evidence that ...
- STDs are at all-time high, people run to web for at-home test kitson October 27, 2019 at 6:24 pm
FARGO, N.D. (Valley News Live) -- Sexually transmitted diseases are on the rise across the United States. The CDC says cases like gonorrhea, syphilis and chlamydia are at an all-time high. Now people ...
- Sex diseases up sharply in Stark County, nationon October 27, 2019 at 5:27 am
The U.S. Centers for Disease Control and Prevention released a Sexually Transmitted Disease Surveillance Report 2018 on its website Oct. 8, saying syphilis, gonorrhea and chlamydia reached all-time ...
- STDs hit women hardeston October 24, 2019 at 9:49 pm
"Chlamydia and gonorrhea, for example, are two of the leading preventable causes of infertility and ectopic pregnancies in the United States, and on Earth." One reason STDs are sexist: In heterosexual ...
- STDs are sexist, and women are the losers. Here's whyon October 24, 2019 at 5:17 pm
"Chlamydia and gonorrhea, for example, are two of the leading preventable causes of infertility and ectopic pregnancies in the United States, and on Earth." Easily transmitted, more dangerous One ...
- Cooperative research center at LLNL aims to develop vaccines for chlamydiaon October 24, 2019 at 5:59 am
A cooperative research center that aims to develop vaccines for chlamydia has been established by the National Institutes of Health at Lawrence Livermore National Laboratory (LLNL). The new center, to ...
- Most physicians lack on-site antimicrobials for treating gonorrhea and syphilison October 24, 2019 at 3:16 am
The CDC’s annual STD report showed that around 2.4 million cases of chlamydia, gonorrhea and syphilis were reported in the United States in 2018, marking the fifth straight record-breaking year for ...
- As STI Rates Soar, Trump Is Funding Clinics That Don't Believe in Condomson October 23, 2019 at 7:05 pm
Earlier this week, the Centers for Disease Control and Prevention released its annual report on STDs in the United States, announcing that, in 2018, the total number of cases of gonorrhea, chlamydia, ...
- binx health Announces First Patients Benefiting From Single-Visit Test and Treatment for Chlamydia and Gonorrheaon October 17, 2019 at 7:49 am
BOSTON: binx health, the pioneer in anywhere, anytime testing for women's health, today announced the first real-world use of the binx io platform, delivering same-visit diagnosis and treatment for ...
via Bing News